GlassScriptPhysician profile
Islam M Othman
NPI 1700905411
$49,759.52
in general payments reported to CMS, 2019-2025
13 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $11K · 2021: $2,715 · 2022: $4,278 · 2023: $290 · 2024: $100 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $959 · Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $959.03 |
| Food and Beverage | $818.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $44,003.80 | 2019-2025 | General - Therapies |
| Bayer Healthcare Pharmaceuticals INC. | $4,000.00 | 2022 | |
| Philips North America LLC | $1,349.95 | 2025 | Coronary Other, Igt Devices Undivided |
| Amgen INC. | $96.85 | 2023-2024 | Repatha |
| Asahi Intecc USA, INC. | $69.89 | 2019 | |
| Teleflex LLC | $53.43 | 2023 | Guideliner |
| Medtronic, INC. | $50.00 | 2024 | Symplicity G3 |
| Cook Medical LLC | $48.78 | 2023 | Zenith Alpha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.66 | 2019 | |
| Abbott Laboratories | $21.34 | 2022 | |
| Nuwellis, INC. | $12.36 | 2019 | |
| Pfizer INC. | $11.46 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Islam Othman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.